Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations
Journal of Allergy and Clinical Immunology · 2025
DOI: 10.1016/j.jaci.2025.08.005 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Danny M Cohn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Electronic ad…. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Antibodies, Monoclonal, Humanized, Complement C1 Inhibitor Protein, Factor XII. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSL Behring LLC.
Abstract (Originalsprache)
BACKGROUND: Hereditary angioedema (HAE) with normal C1 inhibitor (HAE-nC1INH), including HAE arising from F12 (HAE-FXII) or PLG (HAE-PLG) mutations, has a high unmet therapeutic need. OBJECTIVE: Our aim was to explore long-term prophylaxis with monthly subcutaneous garadacimab (anti-activated factor XII mAb) in patients with HAE-FXII or HAE-PLG. METHODS: Efficacy and safety were evaluated for HAE-FXII or HAE-PLG in open-label phase 2 (a 13-week treatment period [TP1] and subsequent ≥44-week extension period [TP2]; 600 mg of garadacimab during each period) and ongoing phase 3 open-label extension (OLE; garadacimab dose 200 mg) studies. RESULTS: Patients 1 and 2 (HAE-FXII) completed phase 2 and then continued into OLE (total exposure time 42.9 and 40.2 months, respectively); patient 3 (HAE-FXII) discontinued TP1 (because of lack of efficacy). Patients 4 to 6 (HAE-PLG) completed TP1 only. Patients 1 and 2 (HAE-FXII) had a reduction in monthly attack rate (AR) of 88% or more versus run-in during phase 2 (TP1 AR = 0.4 and 0.0 and TP2 AR= 0.1 and 0.2, respectively; run-in = 3.2 for both) and were attack-free during the OLE. The AR was increased for patients 4 and 5 (HAE-PLG) and reduced for patient 6 (HAE-PLG). During TP1, 4 of 6 patients (HAE-FXII [n = 2]; HAE-PLG [n = 2]) experienced treatment-emergent adverse events (TEAEs): patient 1 (HAE-FXII) experienced a garadacimab-related TEAE (mild injection-site reaction), and patient 3 (HAE-FXII) experienced an unrelated serious TEAE (severe HAE attack). Patients 1 and 2 (HAE-FXII) collectively experienced 13 mild or moderate TEAEs during TP2 and 2 mild TEAEs during the OLE. CONCLUSIONS: Garadacimab showed a favorable safety profile in all 6 patients with HAE-nC1INH. Garadacimab also demonstrated efficacy in 2 of the 3 patients with HAE-FXII; a reduction in AR was observed in 1 of the 3 patients with HAE-PLG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: d.m.cohn@amsterdamumc.nl.
- Allergy, Immunology, and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel.
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany.
- AARA Research Center, Dallas, Tex.
- CSL Innovation GmbH, Marburg, Germany.
- CSL Behring, King of Prussia, Pa.
Förderung
- CSL Behring LLC
Zitieren
APA
Cohn, D. M., Reshef, A., Staubach, P., Lumry, W. R., Feuersenger, H., Jacobs, I., Pragst, I., Zuraw, B., & Bork, K. (2025). Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2025.08.005
Vancouver
Cohn DM, Reshef A, Staubach P, Lumry WR, Feuersenger H, Jacobs I, et al. Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2025.08.005
BibTeX
@article{Cohn2025,
author = {Cohn, Danny M and Reshef, Avner and Staubach, Petra and Lumry, William R and Feuersenger, Henrike and Jacobs, Iris and Pragst, Ingo and Zuraw, Bruce and Bork, Konrad},
title = {Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
doi = {10.1016/j.jaci.2025.08.005}
}
EUVIMED